[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20212034T1 - Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe - Google Patents

Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe Download PDF

Info

Publication number
HRP20212034T1
HRP20212034T1 HRP20212034TT HRP20212034T HRP20212034T1 HR P20212034 T1 HRP20212034 T1 HR P20212034T1 HR P20212034T T HRP20212034T T HR P20212034TT HR P20212034 T HRP20212034 T HR P20212034T HR P20212034 T1 HRP20212034 T1 HR P20212034T1
Authority
HR
Croatia
Prior art keywords
antibody
pharmaceutical preparation
checkpoint inhibitor
antigen
cancer
Prior art date
Application number
HRP20212034TT
Other languages
English (en)
Inventor
Abhishek Datta
Allan CAPILI
Thomas SCHURPF
Constance MARTIN
Kevin B. Dagbay
Christopher CHAPRON
Stefan WAWERSIK
Christopher LITTLEFIELD
Gregory J. Carven
Alan Buckler
Susan Lin
Justin W. JACKSON
Anthony Cooper
Andrew Avery
Matthew SALOTTO
Caitlin STEIN
Original Assignee
Scholar Rock, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock, Inc. filed Critical Scholar Rock, Inc.
Publication of HRP20212034T1 publication Critical patent/HRP20212034T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Claims (14)

1. Protutijelo ili njegov fragment koji veže antigen, naznačeno time, da se veže na svaki od sljedećih antigenskih kompleksa: i) ljudski LTBP1-proTGFβ1; ii) ljudski LTBP3-proTGFβ1; iii) ljudski GARP-proTGFβ1; i iv) ljudski LRRC33-proTGFβ1; pri čemu protutijelo ili njegov fragment koji veže antigen sadrži varijabilnu domenu teškog lanca prema SEQ ID NO: 13 i varijabilnu domenu lakog lanca prema SEQ ID NO: 15.
2. Protutijelo ili njegov fragment koji veže antigen, prema patentnom zahtjevu 1, naznačeno time, da se radi o ljudskom podtipu IgG4 ili IgG1.
3. Farmaceutski pripravak, naznačen time, da sadrži protutijelo ili njegov fragment koji veže antigen prema bilo kojem od prethodnih patentnih zahtjeva, i farmaceutski prihvatljiv nosač.
4. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time, da nadalje sadrži inhibitor kontrolne točke u istom farmaceutski prihvatljivom nosaču.
5. Farmaceutski pripravak prema patentnom zahtjevu 3 ili 4, naznačen time, da je za uporabu u liječenju raka.
6. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time, da je za uporabu u liječenju mijelofibroze.
7. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 5, gdje je u ovisnosti s patentnim zahtjevom 3, naznačen time, da se farmaceutski pripravak koristi u kombinaciji s inhibitorom kontrolne točke.
8. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 5, naznačen time, da pojedinac ima primarnu ili stečenu otpornost na liječenje raka, pri čemu je liječenje raka opcionalno terapija inhibicijom kontrolne točke, kemoterapija i/ili radijacijska terapija.
9. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 8, naznačen time, da liječenje obuhvaća primjenu pripravka, zajedno s dodatnom terapijom protiv raka odabranom iz skupine koju čine inhibitor kontrolne točke, kemoterapija i radijacijska terapija i/ili cjepivo protiv raka.
10. Farmaceutski pripravak, ili farmaceutski pripravak za uporabu, prema bilo kojem od patentnih zahtjeva 4, 7 ili 9, naznačen time, da se inhibitor kontrolne točke bira iz skupine koju čine antagonist PD-1, antagonist PD-L1, fuzijski protein PD-L1 ili PD-L2, antagonist CTLA4, agonist GITR, protutijelo anti-ICOS, protutijelo anti-ICOSL, protutijelo anti-B7H3, protutijelo anti-B7H4, protutijelo anti-TIM3, protutijelo anti-LAG3, protutijelo anti-OX40, protutijelo anti-CD27, protutijelo anti-CD70, protutijelo anti-CD47, protutijelo anti-41BB, protutijelo anti-PD-1, onkolitički virus, inhibitor PARP, nivolumab, pembrolizumab, BMS-936559, atezolizumab, avelumab, durvalumab, ipilimumab, tremelimumab, IMP-321, BMS-986016 i lirilumab.
11. Farmaceutski pripravak, ili farmaceutski pripravak za uporabu, prema patentnom zahtjevu 10, naznačen time, da inhibitor kontrolne točke je antagonist PD-1 ili antagonist PD-L1.
12. Farmaceutski pripravak, ili farmaceutski pripravak za uporabu, prema patentnom zahtjevu 11, naznačen time, da inhibitor kontrolne točke jest protutijelo anti-PD-1.
13. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 5 ili 7 do 12, naznačen time, da rak uključuje čvrsti tumor.
14. Postupak za proizvodnju farmaceutskog pripravka, naznačen time, da obuhvaća: (i) pribavljanje protutijela ili njegovog fragmenta u skladu s bilo kojim od patentnih zahtjeva 1 do 2; (ii) formuliranje protutijela ili njegovog fragmenta koji veže antigen u farmaceutski pripravak s farmaceutski prihvatljivim nosačem.
HRP20212034TT 2018-07-11 2019-07-11 Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe HRP20212034T1 (hr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201862696774P 2018-07-11 2018-07-11
US201862696752P 2018-07-11 2018-07-11
US201862718196P 2018-08-13 2018-08-13
US201862722081P 2018-08-23 2018-08-23
US201862737534P 2018-09-27 2018-09-27
US201862758180P 2018-11-09 2018-11-09
US201862757917P 2018-11-09 2018-11-09
US201962810263P 2019-02-25 2019-02-25
US201962827552P 2019-04-01 2019-04-01
EP19185896.8A EP3677278B1 (en) 2018-07-11 2019-07-11 Isoform selective tgfbeta1 inhibitors and use thereof

Publications (1)

Publication Number Publication Date
HRP20212034T1 true HRP20212034T1 (hr) 2022-04-01

Family

ID=67437706

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20212034TT HRP20212034T1 (hr) 2018-07-11 2019-07-11 Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe

Country Status (14)

Country Link
US (2) US11130803B2 (hr)
EP (2) EP4019046A1 (hr)
CY (1) CY1125076T1 (hr)
DK (1) DK3677278T3 (hr)
ES (1) ES2905160T3 (hr)
HR (1) HRP20212034T1 (hr)
HU (1) HUE056501T2 (hr)
LT (1) LT3677278T (hr)
MA (1) MA52165A (hr)
PL (1) PL3677278T3 (hr)
PT (1) PT3677278T (hr)
RS (1) RS62914B1 (hr)
SI (1) SI3677278T1 (hr)
SM (1) SMT202100703T1 (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100703T1 (it) 2018-07-11 2022-01-10 Scholar Rock Inc Inibitori di tgfbeta1 isoforma-selettivi e loro utilizzo
PE20230259A1 (es) 2020-03-19 2023-02-07 Genentech Inc Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
WO2022256723A2 (en) * 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20230144192A1 (en) * 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
CN114236137A (zh) * 2021-12-17 2022-03-25 中山大学·深圳 一种转化生长因子β的体外检测试剂盒及其应用
CN115501322A (zh) * 2022-09-23 2022-12-23 西南交通大学 用于肿瘤免疫治疗的多肽药物偶联物、载药系统、药物组合系统及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
EP2386575A3 (en) 2000-06-29 2011-11-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
WO2005023870A1 (ja) 2003-09-04 2005-03-17 Riken TGF-β活性化制御領域の切断面を認識する抗体
CA2930677A1 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009149185A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
PL2780368T3 (pl) 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
EP2916867A4 (en) 2012-11-06 2016-10-05 Scholar Rock Inc COMPOSITIONS AND METHOD FOR MODULATING CELL SIGNALING
PL2981822T4 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
CA2947967A1 (en) 2014-05-06 2015-11-12 Scholar Rock, Inc. Compositions and methods for growth factor modulation
AU2015342936B2 (en) 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
AU2016297248A1 (en) 2015-07-22 2018-02-15 Scholar Rock, Inc. GDF11 binding proteins and uses thereof
IL305148A (en) 2015-09-15 2023-10-01 Scholar Rock Inc Anti-pro/hidden myostatin antibodies and their uses
IL307835A (en) 2016-03-11 2023-12-01 Scholar Rock Inc Tgfb1-binding immunoglobulins and use thereof
BR112019000621A2 (pt) 2016-07-14 2019-04-24 Scholar Rock, Inc. anticorpos tgfss, métodos e usos
PE20191661A1 (es) 2017-01-06 2019-11-11 Scholar Rock Inc Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
EP3658583A1 (en) 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
SMT202100703T1 (it) 2018-07-11 2022-01-10 Scholar Rock Inc Inibitori di tgfbeta1 isoforma-selettivi e loro utilizzo
EP3820896A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. TGFbeta1 INHIBITORS AND USE THEREOF
WO2020014460A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF

Also Published As

Publication number Publication date
MA52165A (fr) 2021-06-02
US20220064275A1 (en) 2022-03-03
EP4019046A1 (en) 2022-06-29
US20200079840A1 (en) 2020-03-12
HUE056501T2 (hu) 2022-02-28
EP3677278A1 (en) 2020-07-08
LT3677278T (lt) 2022-01-10
SMT202100703T1 (it) 2022-01-10
RS62914B1 (sr) 2022-03-31
US11130803B2 (en) 2021-09-28
US12122823B2 (en) 2024-10-22
ES2905160T3 (es) 2022-04-07
CY1125076T1 (el) 2023-06-09
SI3677278T1 (sl) 2022-01-31
EP3677278B1 (en) 2021-11-10
DK3677278T3 (da) 2022-01-10
PL3677278T3 (pl) 2022-02-28
PT3677278T (pt) 2022-02-03

Similar Documents

Publication Publication Date Title
HRP20212034T1 (hr) Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
HRP20210440T1 (hr) Kombinirana terapija za rak
HRP20201404T1 (hr) Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
Aranda et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
JP2020099324A5 (hr)
HRP20221226T1 (hr) Protutijela protiv pd-1 i postupci njihove upotrebe
HRP20210399T1 (hr) Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
HRP20190749T1 (hr) Ljudska antitijela na pd-l1
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
JP2018532383A5 (hr)
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
JP2018501197A5 (hr)
JP2020516240A5 (hr)
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
IL253462B (en) Treatment of cancer with anti-lap monoclonal antibodies
RU2017105118A (ru) Нейтрализация ингибирующих путей в лимфоцитах
JP2017535257A5 (hr)
RU2018134065A (ru) Антитела, специфические к рецептору полиовируса (pvr) человека
IL308805A (en) Anti-pd-1 antibodies for treatment of lung cancer
HRP20230060T1 (hr) Antitijela protiv ox40 i njihova primjena
JP2018508483A5 (hr)
HRP20220014T1 (hr) Postupci liječenja raka kože davanjem inhibitora pd-1
JP2020514310A5 (hr)
JP2018508512A5 (hr)
JP2017501157A5 (hr)